Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | NPC1 | O15118 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | RRM1 | P23921 | 4/20 | 0.77 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.77 |
| ▸ | IDO1 | P14902 | 2/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | G6PD | P11413 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414666 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16713131 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1679411 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2847708 | 0.90 | MEN1 (0.85) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL683715 | 0.90 | MEN1 (0.85) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL11406319 | 0.87 | MEN1 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10785019 | 0.87 | MEN1 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16724452 | 0.86 | PAX8 (0.76) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14223812 | 0.85 | MEN1 (0.81) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16582347 | 0.85 | PAX8 (0.74) | PAX8MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240350553-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4415743-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | Reverse Bioengineering, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064577-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210180013-A1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170304288-A1 | Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases | TEXAS SOUTHERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100130450-A1 | Methods of Treating Fungal Infections | NORTHEASTERN UNIVERSITY (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130450-A1 | Methods of Treating Fungal Infections | NORTHEASTERN UNIVERSITY (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130450-A1 | Methods of Treating Fungal Infections | NORTHEASTERN UNIVERSITY (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2146702-A2 | METHODS OF TREATING FUNGAL INFECTIONS | NorthEastern University (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| WO-2008137128-A2 | METHODS OF TREATING FUNGAL INFECTIONS | NORTHEASTERN UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008073961-A9 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | UNIV EMORY (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008073961-A2 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | PAX8 3588/4885MEN1 3014/4885KMT2A 3171/4885 |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | TNNC1, MYOF, MBNL1 | PAX8 422/4885MEN1 4431/4885KMT2A 3698/4885 |
| US-20170304288-A1 | Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases | METAP1, METAP2, DNPEP | PAX8 3934/4885MEN1 607/4885KMT2A 876/4885 |
| US-20100130450-A1 | Methods of Treating Fungal Infections | ERG28, DPM1, COXFA4L2 | PAX8 4592/4885MEN1 1822/4885KMT2A 4135/4885 |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | SNRPE, NSUN2, SNRPA | PAX8 2117/4885MEN1 3636/4885KMT2A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.